Bavarian Nordic (OMX:BAVA) announced today the initiation of a clinical trial of BN-Brachyury, a novel cancer immunotherapy candidate designed to target brachyury, a key driver of cancer metastasis in several tumor types. As quoted in the press release: “The brachyury target represents an exciting new approach to attacking multiple cancers and deadly metastasis,” commented Paul …

“The brachyury target represents an exciting new approach to attacking multiple cancers and deadly metastasis,” commented Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. “Based on clinical results to date, we believe that BN-Brachyury may be a viable treatment option for patients with various forms of cancer. We look forward to further expanding the program with a Phase 2 study later this year in patients with chordoma – a rare tumor of the spine known to overexpress brachyury, for which there are currently no systemic treatments of proven efficacy available.”

Click here to read the full press release.